Cargando…

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer

The purpose of this study was to examine the effects of ZD6126, a novel vascular-targeting agent, on tumour growth and angiogenesis in an orthotopic model of gastric cancer. TMK-1 human gastric adenocarcinoma cells were injected into the gastric wall of nude mice. After the tumours were established...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCarty, M F, Takeda, A, Stoeltzing, O, Liu, W, Fan, F, Reinmuth, N, Akagi, M, Bucana, C, Mansfield, P F, Ryan, A, Ellis, L M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410155/ https://www.ncbi.nlm.nih.gov/pubmed/14760388 http://dx.doi.org/10.1038/sj.bjc.6601490

Ejemplares similares

Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis
por: Stoeltzing, O, et al.
Publicado: (2002)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells
por: Akagi, M, et al.
Publicado: (2003)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer
por: Liu, W, et al.
Publicado: (2004)

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
por: Sewell, J M, et al.
Publicado: (2002)

Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
por: Alajez, Nehad M, et al.
Publicado: (2012)

Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis
por: Natatsuka, Rie, et al.
Publicado: (2015)

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
por: Magné, N, et al.
Publicado: (2003)

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model
por: Sandström, M, et al.
Publicado: (2004)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
por: Höpfner, M, et al.
Publicado: (2003)

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
por: Magné, N, et al.
Publicado: (2002)

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer
por: Magné, N, et al.
Publicado: (2002)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
por: Shaheen, R M, et al.
Publicado: (2001)

Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model
por: Yashiro, M, et al.
Publicado: (2009)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Gastric peritoneal carcinomatosis - a retrospective review
por: Tan, Hwee Leong, et al.
Publicado: (2017)

Gastric Cancer Peritoneal Carcinomatosis Risk Score
por: Ji, Liang, et al.
Publicado: (2019)

Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma
por: Song, Shumei, et al.
Publicado: (2021)

Surgical Treatment of Peritoneal Carcinomatosis from Gastric Cancer
por: Turaga, Kiran K., et al.
Publicado: (2012)

Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis
por: Leiting, Jennifer L, et al.
Publicado: (2018)

RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis
por: Kim, Hee Kyung, et al.
Publicado: (2019)

Gastric adenocarcinoma peritoneal carcinomatosis: a narrative review
por: Green, Benjamin L., et al.
Publicado: (2022)

ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
por: Williams, K J, et al.
Publicado: (2002)

Diffuse Gastric Cancer with Peritoneal Carcinomatosis Can Mimic Crohn's Disease
por: Hommel, C., et al.
Publicado: (2012)

Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model
por: Chiu, B, et al.
Publicado: (2014)

Peritoneal Tuberculosis Mimicking Peritoneal Carcinomatosis
por: Akce, Mehmet, et al.
Publicado: (2014)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model
por: Mukherjee, P, et al.
Publicado: (2002)

The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
por: Montori, Giulia, et al.
Publicado: (2014)

Photoimmunotherapy of Gastric Cancer Peritoneal Carcinomatosis in a Mouse Model
por: Sato, Kazuhide, et al.
Publicado: (2014)

Conversion Surgery for Patients with Advanced Gastric Cancer with Peritoneal Carcinomatosis
por: Lee, Ting-Ying, et al.
Publicado: (2021)

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
por: Reed, M D, et al.
Publicado: (2013)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis
por: Ellison, Lynne M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ntrlurif88pufl2cm6v45us2rp